• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Ul­tragenyx nix­es plan to seek quick OK for rare dis­ease drug in Eu­rope

9 years ago
R&D

PTC shares rock­et up as Eu­ro­pean reg­u­la­tors of­fer a thumbs-up on Duchenne drug mar­ket­ing

9 years ago
R&D

Don­ald Trump sends a vague­ly word­ed love let­ter to bio­phar­ma as stock ral­ly con­tin­ues

9 years ago
People
Pharma

Klein­er Perkins-backed El­celyx says its re­for­mu­lat­ed met­formin worked in a PhI­Ib di­a­betes study

9 years ago
R&D

Adap­ti­m­mune surges af­ter FDA lifts par­tial hold; An­thera tanks on PhI­II flop; Kad­mon ax­es staffers in re­struc­tur­ing

9 years ago
News Briefing

Bris­tol-My­ers scores fresh brag­ging rights with PhI­II gas­tric can­cer suc­cess for Op­di­vo

9 years ago
R&D

Bris­tol-My­ers hands over $100M in cash for a new fi­bro­sis drug, beef­ing up NASH fo­cus

9 years ago
Pharma

Cell Med­ica signs up for an off-the-shelf CAR-T col­lab­o­ra­tion with Bay­lor

9 years ago
R&D

As­traZeneca ax­es an­oth­er R&D track on dur­val­um­ab af­ter once again falling be­hind ri­vals

9 years ago
R&D

Crushed by a PhI­II flop, No­vavax slash­es jobs as it looks to chop out up to $100M in costs

9 years ago
R&D

Cel­gene EVP Rich Bag­ger makes Politi­co’s short list for Trump’s Cab­i­net

9 years ago
R&D

Bris­tol-My­er's Op­di­vo teams up with In­fin­i­ty's last hope

9 years ago
News Briefing

Kite gives it­self a lit­tle more time to fin­ish FDA ap­pli­ca­tion for KTE-C19

9 years ago
R&D
Pharma

Bio­phar­ma shares ral­ly as Don­ald Trump scores a stun­ning up­set

9 years ago
Pharma

As elec­tion storm gath­ered, Ar­row­head drops word about a clin­i­cal hold

9 years ago
R&D

Prop 61 goes down in flames, torch­ing a na­tion­al drug price con­trol mod­el

9 years ago
Pharma

Cure­Vac grabs a $29.5M round to fu­el its mR­NA de­vel­op­ment ef­forts

9 years ago
R&D

Can AI ac­cel­er­ate drug R&D? J&J of­fers up some mol­e­cules to try it on

9 years ago
AI

Stan­ford team preps first hu­man CRISPR study for sick­le cell dis­ease cure; Shkre­li fin­gers his for­mer at­tor­neys

9 years ago
News Briefing

Ver­sant’s glob­al biotech team is re­load­ing with $350M-plus fund

9 years ago
R&D

Car­dio event forces FDA to halt a Penn PhII study for mul­ti­ple myelo­ma

9 years ago
R&D

It’s End­points News' is­sue #100: The new dai­ly biotech pub now has a lit­tle his­to­ry

9 years ago
Bioregnum
Opinion

Car­dio drug at The Med­i­cines Co gets the heave-ho. (But they pre­fer PC­SK9 any­way.)

9 years ago
R&D

Ther­a­pix Bio in the hunt for $12M mi­cro IPO; Prog­en­ics bags $50M loan; Juno is­n't go­ing any­where, for now

9 years ago
News Briefing
First page Previous page 1171117211731174117511761177 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times